NEW YORK (GenomeWeb News) — NextGen and Kemp Biotechnologies will co-market their fee-for-service offerings, NextGen said today.
UK-based NextGen is a so-called “gene-to-protein” company, whereas Kemp provides expertise in cell culture, protein expression, and protein purification services.
Under the agreement, NextGen will offer Kemp’s pure proteins for pre-clinical research.
NextGen said the alliance will offer soluble active proteins that have been derived from gene sequences that are associated with disease in milligram to multi-gram quantities for structure determination, screening, characterization, or pre-clinical research studies.
Kemp also will transfer its transient mammalian expression technology to NextGen, which the company said will add to the range of protein-expression systems it already offers.
Financial terms of the agreement were not released.